Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: A 2-year case control study

Lung

Volumn 191, Issue 5, 2013, Pages 483-489

  Panopoulos, Stylianos T ^a   Bournia, Vassiliki Kalliopi ^a   Trakada, Georgia ^a   Giavri, Irene ^a   Kostopoulos, Charalambos ^a   Sfikakis, Petros P ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cyclophosphamide; Interstitial lung disease; Mycophenolate mofetil; Mycophenolate sodium; Systemic sclerosis

Indexed keywords

CARBON MONOXIDE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MALE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; TOTAL LUNG CAPACITY;

ADULT; ANTI-INFLAMMATORY AGENTS; CASE-CONTROL STUDIES; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; TOTAL LUNG CAPACITY; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84884818538     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-013-9499-8     Document Type: Article

References (29)

1. Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G (2013) Scleroderma lung disease. Eur Respir Rev 22(127):6-19. doi: 10.1183/09059180. 00005512
2. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 354(25):2655-2666. doi: 10.1056/NEJMoa055120
3. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM (2006) A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 54(12):3962-3970. doi: 10.1002/art.22204
4. Nihtyanova SI, Brough GM, Black CM, Denton CP (2007) Mycophenolate mofetil in diffuse cutaneous systemic sclerosis - a retrospective analysis. Rheumatology (Oxford) 46(3):442-445. doi: 10.1093/rheumatology/kel244
5. Tzouvelekis A, Galanopoulos N, Bouros E, Kolios G, Zacharis G, Ntolios P, Koulelidis A, Oikonomou A, Bouros D (2012) Effect and safety of mycophenolate mofetil or sodium in systemic sclerosis-associated interstitial lung disease: a meta-analysis. Pulm Med 2012:143637. doi: 10.1155/2012/143637
6. Simeon-Aznar CP, Fonollosa-Pla V, Tolosa-Vilella C, Selva-O'Callaghan A, Solans-Laque R, Vilardell-Tarres M (2011) Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 30(11):1393-1398. doi: 10.1007/s10067-011-1823-1
7. Gerbino AJ, Goss CH, Molitor JA (2008) Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest 133(2):455-460. doi: 10.1378/chest.06-2861
8. Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI (2010) Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 29(10):1167-1168. doi: 10.1007/s10067-010-1498-z
9. Liossis SN, Bounas A, Andonopoulos AP (2006) Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 45(8):1005-1008. doi: 10.1093/rheumatology/kei211
10. Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, Meehan RT, Brown KK (2006) Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 130(1):30-36. doi: 10.1378/chest.130.1.30
11. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, King TE Jr, Golden JA (2008) Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med 102(1):150-155. doi: 10.1016/j.rmed.2007.07.021
12. Vanthuyne M, Blockmans D, Westhovens R, Roufosse F, Cogan E, Coche E, Nzeusseu Toukap A, Depresseux G, Houssiau FA (2007) A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 25(2):287-292
13. Panopoulos ST, Bournia VK, Sfikakis PP (2013) Is vasculopathy associated with systemic sclerosis more severe in men? J Rheumatol 40(1):46-51. doi: 10.3899/jrheum.120667
14. American Thoracic Society (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161(2 Pt 1):646-664
15. Warrick JH, Bhalla M, Schabel SI, Silver RM (1991) High resolution computed tomography in early scleroderma lung disease. J Rheumatol 18(10):1520-1528
16. Desai SR, Veeraraghavan S, Hansell DM, Nikolakopolou A, Goh NS, Nicholson AG, Colby TV, Denton CP, Black CM, du Bois RM, Wells AU (2004) CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 232(2):560-567. doi: 10.1148/radiol.2322031223
17. de Lauretis A, Veeraraghavan S, Renzoni E (2011) Review series: aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis 8(1):53-82. doi: 10.1177/1479972310393758
18. Khanna D, Furst DE, Clements PJ, Tashkin DP, Eckman MH (2008) Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. Med Decis Making 28(6):926-937. doi: 10.1177/0272989X08317015
19. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB, Wallace WA, Wells AU, Whyte MK, Wilsher ML (2008) Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 63(Suppl 5):v1-v58. doi: 10.1136/thx.2008.101691
20. Papiris SA, Manali ED, Kolilekas L, Kagouridis K, Triantafillidou C, Tsangaris I, Roussos C (2010) Clinical review: idiopathic pulmonary fibrosis acute exacerbations - unravelling Ariadne's thread. Crit Care 14(6):246. doi: 10.1186/cc9241
21. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU (2011) Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 184(12):1382-1389. doi: 10.1164/rccm.201105-0840OC
22. Behr J (2011) A small change in FVC but a big change for IPF: defining the minimal clinically important difference. Am J Respir Crit Care Med 184(12):1329-1330. doi: 10.1164/rccm.201110-1794ED
23. Khanna D, Roth MD, Furst DE, Clements PJ, Goldin J, Arriola E, Kotlerman J, Tseng C, Kim G, Elashoff G, Tashkin, Scleroderma Lung Study II Research Group (2013) Double-blind comparison of mycophenolate mofetil and oral cyclophosphamide for treatment of scleroderma-related interstitial lung disease (Scleroderma Lung Study [SLS] II): rationale, design, methods, baseline characteristics and patient disposition. Paper presented at the EULAR Conference, Madrid, Spain, June 2013
24. Fischer A, Brown KK, Du Bois RM, Frankel SK, Cosgrove GP, Fernandez-Perez ER, Huie TJ, Krishnamoorthy M, Meehan RT, Olson AL, Solomon JJ, Swigris JJ (2013) Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol. doi: 10.3899/jrheum.121043
25. Mendoza FA, Nagle SJ, Lee JB, Jimenez SA (2012) A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J Rheumatol 39(6):1241-1247. doi: 10.3899/jrheum.111229
26. Herrick AL, Lunt M, Whidby N, Ennis H, Silman A, McHugh N, Denton CP (2010) Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis. J Rheumatol 37(1):116-124. doi: 10.3899/jrheum.090668
27. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, Corte TJ, Sander CR, Ratoff J, Devaraj A, Bozovic G, Denton CP, Black CM, du Bois RM, Wells AU (2008) Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 177(11):1248-1254. doi: 10.1164/rccm.200706-877OC
28. Khanna D, Seibold JR, Wells A, Distler O, Allanore Y, Denton C, Furst DE (2010) Systemic sclerosis-associated interstitial lung disease: lessons from clinical trials, outcome measures, and future study design. Curr Rheumatol Rev 6(2):138-144
29. Au K, Khanna D, Clements PJ, Furst DE, Tashkin DP (2009) Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Curr Rheumatol Rep 11(2):111-119